Safety and effectiveness of induction chemoimmunotherapy followed by definitive radiotherapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma

Table 1 Baseline patient characteristics, n (%)

Characteristics	Data
Sex
Male	75 (93.8)
Female	5 (6.2)
Age, year, median (range)	63 (44-75)
Length of primary focus, cm, median (range)	7 (2-17)
Tumor location
Cervical segment	1 (1.2)
Upper thoracic segment	13 (16.3)
Middle thoracic segment	36 (45.0)
Inferior thoracic segment	30 (37.5)
Clinical T stage
T1	2 (2.5)
T2	16 (20.0)
T3	54 (67.5)
T4	8 (10.0)
Clinical N stage
N0	3 (3.7)
N1	37 (46.3)
N2	21 (26.3)
N3	19 (23.7)
Clinical M stage
M0	69 (86.2)
M1	11 (13.8)
Radiotherapy regimens
Chemoradiotherapy	37(46.3)
Radiotherapy alone	43 (53.7)
Radiation dose
≤ 50 Gy	15 (18.8)
> 50 Gy	65 (81.2)
Induction chemotherapy regimen
Paclitaxel-based combination of platinum	78 (97.5)
Fluorouracil-based combination of platinum	2 (2.5)
Induction immunotherapy regimen
Camrelizumab	45 (56.2)
Pembrolizumab	14 (17.5)
Sintilimab	10 (12.5)
Tislelizumab	5 (6.2)
Nivolumab	1 (1.3)
Toripalimab	1 (1.3)
Durvalumab	4 (5.0)
Concurrent chemotherapy regimen
Paclitaxel-based combination of platinum	27 (88.8)
Single-agent albumin paclitaxel	2 (2.5)
Single-agent tegafur	7 (8.7)
Reasons for no surgery
Unresectable or medically inoperable	57 (71.3)
Refusal of surgery	23 (28.7)

T: Tumor; N: Node; M: Metastasis.